Asbury R F, Blessing J A, Mortel R, Homesley H D, Malfetano J
Am J Clin Oncol. 1987 Aug;10(4):299-301. doi: 10.1097/00000421-198708000-00008.
Twenty-one evaluable patients with advanced squamous-cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Nineteen had prior chemotherapy. One patient had a partial response; six had stable disease; 14 had increasing disease; and two were unevaluable for response. There was a single life-threatening toxic episode. Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated cervical carcinoma patients.
